Search
AK158D1, Developed by Akeso Inc., Receives Approval for Phase I Clinical Trial in Advanced Solid Tumors
1 day ago /
Read about 0 minute
Author：小编
On September 17, Akeso Inc. made a public announcement stating that its self-developed, groundbreaking EGFR/Trop2 bispecific Antibody-Drug Conjugate (ADC) medication, AK158D1, has been granted approval by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA). This approval paves the way for the commencement of a Phase I clinical trial aimed at treating advanced malignant solid tumors.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
